Linked Life Data

7764683

Source:http://linkedlifedata.com/resource/pubmed/id/7764683

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1994-6-9
pubmed:abstractText
The interplay between chemical and biological approaches to drug discovery and development is increasing with the advent of combinatorial methods that accelerate the output of screening programs and the development of genetically modified microorganisms able to make new metabolites and larger amounts of known ones. Actinomycetes, the most prolific microbial source of known drugs, can produce new aromatic compounds by manipulation of the Type II polyketide synthase genes as well as analogs of existing macrolide antibiotics, unavailable by chemical synthesis, through targeted mutation of specific biosynthetic genes. Genetic alteration of pathways to aminoglycoside and oligopeptide antibiotics should offer equally promising approaches to manufacturing novel metabolites. When coupled with DNA-based prescreening of microbial isolates for genes associated with known pharmacologically active agents, these new genetic-based approaches are creating an expanded role for microorganisms in drug research.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
B
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0733-222X
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
375-80
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Drug synthesis by genetically engineered microorganisms.
pubmed:affiliation
School of Pharmacy, University of Wisconsin, Madison 53706.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review